PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/5/1257 |
| _version_ | 1797567800519163904 |
|---|---|
| author | Foteinos-Ioannis Dimitrakopoulos Achilleas Nikolakopoulos Anastasia Kottorou Fotini Kalofonou Elias Liolis Theodora Frantzi Ioannis Pyrousis Angelos Koutras Thomas Makatsoris Haralabos Kalofonos |
| author_facet | Foteinos-Ioannis Dimitrakopoulos Achilleas Nikolakopoulos Anastasia Kottorou Fotini Kalofonou Elias Liolis Theodora Frantzi Ioannis Pyrousis Angelos Koutras Thomas Makatsoris Haralabos Kalofonos |
| author_sort | Foteinos-Ioannis Dimitrakopoulos |
| collection | DOAJ |
| description | Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (<i>p</i> < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (<i>p</i> < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank <i>p</i> = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS. |
| first_indexed | 2024-03-10T19:47:37Z |
| format | Article |
| id | doaj.art-651893c6505e4df9a5aaf2a9215a3bc1 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:47:37Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-651893c6505e4df9a5aaf2a9215a3bc12023-11-20T00:40:53ZengMDPI AGCancers2072-66942020-05-01125125710.3390/cancers12051257PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) InhibitorsFoteinos-Ioannis Dimitrakopoulos0Achilleas Nikolakopoulos1Anastasia Kottorou2Fotini Kalofonou3Elias Liolis4Theodora Frantzi5Ioannis Pyrousis6Angelos Koutras7Thomas Makatsoris8Haralabos Kalofonos9Division of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceDivision of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceClinical and Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rion, GreeceImperial Healthcare Trust-Oncology, London W2 1NY, UKDivision of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceDivision of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceClinical and Molecular Oncology Laboratory, Medical School, University of Patras, 26504 Rion, GreeceDivision of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceDivision of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceDivision of Oncology, Department of Medicine, University Hospital of Patras, 26504 Rion, GreeceImmunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (<i>p</i> < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (<i>p</i> < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank <i>p</i> = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS.https://www.mdpi.com/2072-6694/12/5/1257NSCLCimmunotherapylung cancerprognosticpredictivebiomarkers |
| spellingShingle | Foteinos-Ioannis Dimitrakopoulos Achilleas Nikolakopoulos Anastasia Kottorou Fotini Kalofonou Elias Liolis Theodora Frantzi Ioannis Pyrousis Angelos Koutras Thomas Makatsoris Haralabos Kalofonos PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors Cancers NSCLC immunotherapy lung cancer prognostic predictive biomarkers |
| title | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
| title_full | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
| title_fullStr | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
| title_full_unstemmed | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
| title_short | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
| title_sort | pios patras immunotherapy score score is associated with best overall response progression free survival and post immunotherapy overall survival in patients with advanced non small cell lung cancer nsclc treated with anti program cell death 1 pd 1 inhibitors |
| topic | NSCLC immunotherapy lung cancer prognostic predictive biomarkers |
| url | https://www.mdpi.com/2072-6694/12/5/1257 |
| work_keys_str_mv | AT foteinosioannisdimitrakopoulos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT achilleasnikolakopoulos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT anastasiakottorou piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT fotinikalofonou piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT eliasliolis piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT theodorafrantzi piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT ioannispyrousis piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT angeloskoutras piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT thomasmakatsoris piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT haralaboskalofonos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors |